KARYOPHARM THERAPEUTICS INC (KPTI) Stock News

USA - NASDAQ:KPTI - US48576U2050 - Common Stock

5.03 USD

-0.74 (-12.82%)

Last: 10/8/2025, 12:48:45 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KPTI Latest News, Press Relases and Analysis

All

Press Releases

5 hours ago - By: Chartmill - Mentions: TRX ESPR XTLB PCSA ...

News Image

These stocks that are showing activity before the opening bell on Wednesday.

5 hours ago - By: Benzinga - Mentions: XTLB ESPR XBIO UPC ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

6 hours ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

7 days ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 days ago - By: Benzinga - Mentions: DYAI ICU KALV SXTC ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

a month ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

a month ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research - Mentions: VXRT

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

2 months ago - By: Zacks Investment Research - Mentions: COLL

Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research - Mentions: ARDX

Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

3 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Present at the Jefferies Global Healthcare Conference

4 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Zacks Investment Research

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

5 months ago - By: Zacks Investment Research

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

5 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

5 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

5 months ago - By: Zacks Investment Research - Mentions: OPTN

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

5 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

5 months ago - By: Zacks Investment Research - Mentions: NBIX

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

5 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Antengene Corporation Limited

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

7 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)